Related Experiment Video
Updated: Jul 18, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Rational design and development of radiation-sensitizing histone deacetylase inhibitors
Mira Jung1, Alan Kozikowski, Anatoly Dritschilo
1Department of Radiation Medicine, Georgetown University Medical Center, The Research Building, Room E202, Box 571482, 3970 Reservoir Road NW, Washington, DC 20057-1482, USA.
Abstract:
Histone deacetylases (HDACs) offer potentially attractive molecular targets for sensitizing cancers to treatment with radiation therapy. By affecting patterns of gene expression, differentiation, apoptosis, and enhanced responses to therapeutic agents may be induced in cancer cells. Here, we review the drug characteristics underlying design and screening of HDAC inhibitors with a focus on radiation-sensitizing properties. Radiation-sensitizing capacities have been observed in three model systems, squamous carcinoma of head and neck origin (SQ-20B), prostate adenocarcinoma (PC-3), and breast adenocarcinoma (MCF7). Cell-type specificities in radiation-sensitizing properties have been observed. Mechanisms underlying specificity are under investigation.
Insights
Histone deacetylase inhibitors (HDACis) show promise for enhancing cancer radiation therapy. These drugs sensitize cancer cells to radiation, with observed effects varying by cancer type, warranting further investigation into underlying mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Histone deacetylases (HDACs) are implicated in cancer development and progression.
- HDAC inhibitors represent a promising class of targeted cancer therapeutics.
- Modulating gene expression via HDAC inhibition may enhance cancer cell sensitivity to radiation therapy.
Purpose of the Study:
- To review drug characteristics of HDAC inhibitors.
- To focus on the radiation-sensitizing properties of HDAC inhibitors.
- To examine cell-type specificities in HDAC inhibitor-mediated radiosensitization.
Main Methods:
- Literature review of HDAC inhibitors.
- Analysis of drug design and screening for radiosensitizing properties.
- Evaluation of preclinical data in model cancer systems (SQ-20B, PC-3, MCF7).
Main Results:
- HDAC inhibitors demonstrate radiation-sensitizing capacities across different cancer cell lines.
- Observed radiosensitization effects show specificity depending on the cancer cell type.
- Specific cancer models evaluated include squamous carcinoma (SQ-20B), prostate adenocarcinoma (PC-3), and breast adenocarcinoma (MCF7).
Conclusions:
- HDAC inhibitors are potential radiosensitizers in cancer treatment.
- Cell-type specificities in radiosensitization by HDAC inhibitors are evident.
- Further research is needed to elucidate the mechanisms driving these observed specificities.
